Caring For Your Infant With Hemangioma
Infantile hemangiomas are “birth marks” made up of a collection of blood vessels that formed incorrectly and proliferate rapidly. They occur in as many as 5% of infants, making them the most common benign tumor of infancy. Infantile hemangiomas are more common in girls, twins, white infants, and those born premature or with low birth weight. Most are small, resolve on their own, and require no treatment. A small number of hemangiomas have the potential to cause problems, based on their size or their location, and those risk factors are important in the consideration for treatment. Careful monitoring, recognition of risk, and early intervention are key in providing the best care for your infant with hemangioma.
Infantile hemangioma may be present at birth as a superficial, small, red, vascular mark on the skin, or more commonly become evident in the weeks following birth. They have traditionally been called “strawberry hemangiomas.” There is a natural history of uncomplicated infantile hemangiomas: they typically grow rapidly during the first 3 months, most stop growing by 5 months, and most infantile hemangiomas start to involute between 5-12 months of life. The color will change from red to milky-white or gray, the lesion will flatten and shrink, and 90% heal by age 4yr. Even after involution, the skin may be left with thin blood vessels (telangiectasias), redundant skin, or a scar. Some infantile hemangiomas are deeper in the skin, and may have a blue appearance.
As stated above, most infantile hemangiomas are benign. There are well-defined categories of infantile hemangiomas with increased risk for complication: their early recognition and treatment can prevent adverse outcomes. Hemangiomas requiring treatment include:
Those in the “beard-area” or the front of the neck, which may be associated with hemangioma in the airway, which has the potential to block the airway as the hemangioma grows.
Infants with 5 or more cutaneous hemangiomas, which may alert to the possibility of hemangiomas in vital organs like the liver, and may cause strain on the body leading to cardiac failure and severe thyroid dysfunction.
Infantile hemangiomas in areas where their presence may cause functional impairment, e.g. those at the eye potentially impacting vision, and those at the lip/mouth potentially impacting feeding.
Infantile hemangiomas in areas at increased risk for ulceration/bleeding, e.g. those at the lip, upper ear, diaper area, anus, and skin folds of the neck, arm pit, and groin.
Infantile hemangiomas in areas at high risk of scarring or permanent disfigurement, e.g. those at the face and scalp, those at the breast, those with a steep step off (ledge effect), and those greater than 2cm in size or 2mm in depth.
Large, segmental (greater than 5cm) infantile hemangiomas over the head and neck, or lumbosacral area of the back, which may be associated with underlying structural anomalies of the brain, vascular system, spine or spinal cord.
It is recommended that infants with hemangiomas that are high risk for complications be seen by a specialist by 1 month of age. Depending on the location and nature of the hemangioma, specialty consultation may be arranged with a pediatric dermatologist, a pediatric plastic surgeon, and/or an otolaryngologist (ENT surgeon).
Diagnostic studies are generally unnecessary, as infantile hemangiomas are diagnosed by their clinical appearance. Rarely, if the appearance or growth or response to treatment are atypical, a biopsy may be recommended. Ultrasound of the abdomen is indicated in the setting of 5 or more cutaneous hemangiomas, to evaluate for the presence of hemangiomas within the liver. The presence of large segmental hemangiomas, for example over the head and neck or lumbosacral spine, would warrant imaging studies (MRI/MRA) of associated structures like the head, chest, spine and spinal cord.
The first-line treatment of high-risk infantile hemangiomas is oral propranolol. Studies show a mean response of 95%. The precise mechanism of action is unclear, though may be related to its ability to promote vasoconstriction and inhibit angiogenesis (new blood vessel formation). The recommended starting dose is 0.6 mg/kg given twice daily, with a gradual increase to the target dose of 2-3 mg/kg/day. Treatment is recommended for 6 months, and there may be rebound growth in 10-25% of infants when propranolol is discontinued. Propranolol is a beta-blocker, and side effects of propranolol include bradycardia (slow heart rate), hypotension (low blood pressure), hypoglycemia (low blood sugar), lethargy, poor feeding, wheezing, and sleep disturbance. Any child with known congenital heart disease and hemangioma should be seen by their cardiologist for consultation, regarding the safety of propranolol with their underlying cardiac condition. Screening EKG is only indicated for infants with a baseline low or irregular heart rate, and those with a family history of congenital heart disease or rhythm disturbance. Propranolol should be administered with or after feeds, and should be held at times of diminished feeding or vomiting to reduce the risk of hypoglycemia. Side effects , when they occur, are generally mild, and may be managed by lowering the dose of propranolol. Discontinuation of treatment is rarely necessary.
For patients in whom propranolol is contraindicated, poorly tolerated or ineffective, second-line treatment of high-risk infantile hemangiomas is steroids, either orally or by direct injection into the high-risk lesion. Prolonged use of oral steroids is associated with significant side effects (Cushingoid appearance, increased risk for infection, poor growth, high blood pressure, and mood changes), and is thus not recommended.
Low risk lesions do not require treatment, though some clinicians will recommend treating thin, superficial hemangiomas with topical timolol, also a beta-blocker, to slow growth and enhance resolution. Lesions treated with topical timolol have an estimated clearance of over 60%. Since medication may be absorbed through the skin into the bloodstream, a small percentage of infants treated with topical timolol may experience systemic symptoms, including sleep disturbance, bradycardia, and wheezing: these side effects are noted to be more prevalent in premature infants. Surgical interventions during infancy are generally avoided (risk of anesthesia and bleeding), though high-risk lesions that are not responsive to oral propranolol may require surgery. Pulse-dye-laser (PDL) treatment is being used for infantile hemangioma, though it carries the risk of bleeding, ulceration, skin atrophy, and scarring. Both surgery and PDL may be useful in managing persistent skin changes that may result from an infantile hemangioma.
We are here for you. If you have concerns about your infant’s hemangioma, particularly if it is rapidly growing between the 1 month and 2 month check-up appointments, reach out on the portal or schedule an appointment to come see us in the office. Here are some additional resources and community partners that serve our patients with infantile hemangioma:
Plastic Surgeon Dr. Eric Stelnicki (Hollywood) 954-984-1899
Plastic Surgeon Dr. Drew Schnitt (Delray Beach) 855-467-7473
Plastic Surgeon Dr. Chad Perlyn (Miami) 305-278-5951
Dermatologist Dr. Lawrence Schachner (Miami) 305-243-6704
Dermatologist Dr. Ana Duarte (Miami) 305-669-6555
Dermatologist Dr. Anna Falabella (Hollywood) 954-961-1200
ENT Dr. Samuel Ostrower (Coral Springs) 954-265-1616
ENT Dr. Steven Singer (Hollywood) 954-987-5430
ENT Dr. Sandeep Dave (Miami) 786-624-3687
https://hemangiomaeducation.org/
Society for Pediatric Dermatology https://peds derm.net/
PLANTATION
8430 West Broward Blvd Ste 300
Plantation, FL 33324
(954)-473-8588 (fax)
Monday - Fridays
8 am - 5 pm
(Closed for Lunch 12pm-1:30pm)
Saturday
8 am - 12 pm
Sundays & Holidays
Morning Urgent Hours Available For Coral Springs, Only After 8 am
TAMARAC
7489 North University Drive
Tamarac, FL 33321
(954)-722-4888 (fax)
Monday - Friday
8 am - 5 pm
(Closed for Lunch 12pm-1:30pm)
Saturday
8 am - 12pm
Sundays & Holidays
Morning Urgent Hours Available For Coral Springs, Only After 8 am
CORAL SPRINGS
5697 Coral Ridge Dr.
Coral Springs, FL 33076
(954) 510-4800 (fax)
Monday - Friday
8 am - 5 pm
(Closed for Lunch 12pm-1:30pm)
Saturday
8 am - 12pm
Sundays & Holidays
Morning Urgent Hours Available For Coral Springs, Only After 8 am
Miramar
1951 SW 172nd Avenue Ste 200
Miramar, FL 33029
(954) 722-4888 (fax)
Monday & Friday
8 am - 12pm
Saturday
8 am - 12pm
Sundays & Holidays
Morning Urgent Hours Available For Coral Springs, Only After 8 am
© 2023 Children's Medical Association (CMA). All rights reserved.
Designed by Brandiket.com